Shop by goal
Popular compounds
Research resources
Recently viewed
PT-141: Tanning / Libido research guide
Not medical advice. PT-141 is a research compound. This guide does not provide dosing, diagnosis, therapy recommendations, or claims about effects in humans.
What PT-141 is
PT-141 (bremelanotide, Vyleesi) is an FDA-approved MC4R agonist that drives sexual arousal through central hypothalamic signalling rather than peripheral vasodilation - a fundamentally different mechanism than PDE-5 inhibitors.
One-paragraph overview from our research datasheet — still scientific, but faster to read than the full mechanism list below.
Bremelanotide (PT-141) FDA-approved MC4R agonist for HSDD activates hypothalamic sexual arousal pathways via central melanocortin signaling. t½ 2.7 hours SC.
Research contexts
Peer-reviewed literature typically discusses PT-141 in specific experimental settings. The points below reflect how the scientific community frames this compound—not as health claims, but as the research questions being asked.
Research vs. personal use: Literature describes experiments in controlled lab and animal models. This is distinct from any real-world use; our products are for laboratory research only.
Typical study contexts
Why Tanning / Libido research matters
These peptides are studied mainly for how they interact with melanocortin receptors and pigmentation biology. That research is separate from human “tanning products” and stays in controlled scientific contexts.
Mechanisms (technical review)
Our datasheet lists mechanistic themes observed in preclinical work. These are research endpoints, not health claims. They help scientists understand and compare pathways.
Lab handling & preparation
Storage requirements: Lyophilised powder: store in freezer (−20 °C). Reconstituted: refrigerate 1–6 °C, away from sunlight. Use within the validated stability window for the specific batch and formulation. · Learn best practices in our detailed storage guide.
Research dosing context: Literature typically discusses 1.75 mg subcutaneously (FDA-approved dose) · As needed, at least 45 minutes before anticipated sexual activity. Maximum one dose per 24 hours, ≤8 doses per month · SC t½ = 2.7 hr (range 1.9-4.0 hr). Tmax ~1 hr. Vd = 25.0 L. CL = 6.5 L/hr. Protein binding 21%. Excretion: 64.8% urine, 22.8% feces. Most common adverse effect: nausea (40%). Biological effect duration 4-8 hr exceeds plasma half-life. Available as 1.75 mg/0.3 mL autoinjector pen (Vyleesi).
Preparation steps: Follow our detailed reconstitution guide, use the calculator tool for volume confirmation, and always verify purity with the COA reading guide.
Common Questions People Are Asking
What is PT-141?
PT-141 (bremelanotide) is a cyclic melanocortin-receptor agonist peptide that acts centrally on MC4R arousal pathways. It is the molecule approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. New-U's PT-141 is research-grade material supplied for laboratory use only — not the approved drug and not for human use.
What does PT-141 do?
In research and clinical studies PT-141 activates hypothalamic MC4R circuits involved in sexual motivation/arousal — acting on the brain rather than on peripheral blood flow. These are findings for the molecule; New-U supplies research-grade PT-141 for laboratory research only and implies no human effect.
What does PT-141 do for women?
The approved drug (bremelanotide / Vyleesi) is indicated for hypoactive sexual desire disorder in premenopausal women, acting on central MC4R arousal pathways. That is the clinical product; New-U supplies research-grade PT-141 strictly for laboratory research, not for human use.
How long does PT-141 last?
Published pharmacology describes a short plasma half-life of about 2.7 hours, while the functional effect window reported in studies of the molecule spans roughly 4-8 hours — longer than the circulating peptide, reflecting receptor residence time. This is reported research context only — not human-use dosing guidance. New-U supplies PT-141 for laboratory research only.
What does the research on PT-141 actually show?
The pivotal evidence is the RECONNECT program — two identical phase 3 trials in more than 1,200 premenopausal women with HSDD (Kingsberg et al., Obstetrics & Gynecology, 2019) — which reported statistically significant improvements in sexual desire and reductions in associated distress versus placebo, supporting the 2019 FDA approval of Vyleesi. Earlier research also studied the central MC4R mechanism in male erectile function. This is summarised published research about the molecule, not a human-use claim; New-U supplies research-grade PT-141 for laboratory research only.
Is PT-141 FDA approved?
The pharmaceutical bremelanotide (Vyleesi) is FDA-approved for HSDD in premenopausal women. That approval applies to the finished prescription drug — NOT to research-grade material. New-U's PT-141 is an unapproved research powder supplied for laboratory research only.
How is PT-141 different from Viagra or Cialis?
PDE-5 inhibitors like Viagra work peripherally - they relax smooth muscle and improve blood flow to the genital tissue, which helps with the mechanics of erection. They do nothing about desire or arousal. PT-141 works centrally in the brain, activating hypothalamic MC4R circuits that generate sexual motivation. The two classes target completely different steps and can theoretically even be used together.
How is PT-141 different from Melanotan-2?
PT-141 is essentially an active metabolite of MT-2 with a free carboxylic acid at the C-terminus instead of an amide. That single change shifts selectivity toward MC4R-mediated arousal and away from the broader MC1/3/4/5 activity of MT-2 - keeping the sexual effects while reducing pigmentation, nausea, and facial flushing.
Why is nausea the most common side effect?
MC4R is expressed in multiple hypothalamic nuclei including the ones that control nausea and appetite, so central MC4R activation inevitably produces some nausea as a dose-dependent effect. In the Vyleesi clinical trials, around 40% of subjects experienced some nausea at the 1.75 mg dose - it is the predictable consequence of hitting MC4R centrally.
How should PT-141 be stored?
Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. The cyclic structure gives PT-141 good stability in solution within the normal peptide-handling window.
Is this page medical advice? Can I use PT-141 for my health?
No, and no. This article is educational only. We do not provide dosing, medical recommendations, or health claims. Our products are sold strictly for laboratory research, not for personal use of any kind.
Where do I find PT-141 specs, purity certificates and pricing?
Open the shop listing via “View product details.” There you will see batch specs, the Certificate of Analysis (COA), concentration, purity grade, and available SKUs with current pricing.
Related peptide guides
Other compounds researchers often read about alongside PT-141.
Scientific sources & further reading
Primary literature and registries for PT-141, plus mainstream coverage of the peptide category. Research use only - not medical advice.
Databases & literature:
Peptides in the news:
Ready to order? View full product specs
Access concentration, batch info, variants, and current pricing on our shop.
Also known as: PT-141, Bremelanotide, Vyleesi, Bremelanotide Acetate, MC4R Agonist, Cyclic MSH Analogue, Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH
Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.
Shop
Learn
Company
Support
Ways to Pay
Shop by Compound
Shop by Goal
Ships worldwide
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io · @new.u.io